文献速递骨质疏松与代谢性骨病

罗莫佐单抗治疗比利时骨折高风险绝经后骨质疏松女性的成本效益

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
PubMed 文献 · Osteoporos Int · 2024-04-02

本研究从比利时医疗保健视角,采用马尔可夫微观模拟模型,评估罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药及特立帕肽序贯阿仑膦酸钠,在骨折高风险绝经后骨质疏松女性中的成本效益。结果显示罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药具有成本效益,相比特立帕肽序贯阿仑膦酸钠为优势方案。

要点

  • 罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药增加0.12 QALY,增量成本2314欧元,ICER为19978欧元/QALY。
  • 罗莫佐单抗序贯阿仑膦酸钠相比特立帕肽序贯阿仑膦酸钠为优势方案,QALY更高且成本更低。
  • 敏感性分析显示基础病例结果对输入参数的不确定性稳健。

核心结论

  • 在比利时骨折高风险绝经后骨质疏松女性中,罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药具有成本效益,相比特立帕肽序贯阿仑膦酸钠为优势方案。

研究设计与样本

  • 采用马尔可夫微观模拟模型,评估罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药及特立帕肽序贯阿仑膦酸钠的成本效益,时间跨度为终身。
  • 患者每6个月根据骨折风险或死亡在五种健康状态间转换。
  • 模型填充比利时特异性流行病学和成本数据(若有),罗莫佐单抗的骨折风险降低数据来自ARCH研究和已发表的网络Meta分析。
  • 成本从医疗保健视角(NIHDI)纳入,成本效益以每质量调整生命年(QALY)的成本报告,单位为2022年欧元(€)。
  • 进行了确定性敏感性分析(DSA)和概率敏感性分析(PSA)。

主要发现

  • 罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药增加0.12 QALY,增量成本为2314欧元,ICER为19978欧元/QALY。
  • 罗莫佐单抗序贯阿仑膦酸钠相比特立帕肽序贯阿仑膦酸钠为优势方案,QALY更高且成本更低。
  • 敏感性分析显示基础病例结果对输入参数的不确定性稳健。

关键数值与推荐

  • 罗莫佐单抗序贯阿仑膦酸钠相比阿仑膦酸钠单药:增量QALY 0.12,增量成本€2314,ICER €19978/QALY。
  • 罗莫佐单抗序贯阿仑膦酸钠相比特立帕肽序贯阿仑膦酸钠:优势方案(QALY更高且成本更低)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study evaluated the cost-effectiveness of sequential treatment with romosozumab-to-alendronate compared to alendronate monotherapy and teriparatide-to-alendronate, in postmenopausal osteoporotic women from a Belgian healthcare perspective. Romosozumab-to-alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide-to-alendronate for osteoporotic women at high risk of fracture in Belgium. PURPOSE: This study aimed to evaluate the cost-effectiveness of sequential treatment with romosozumab followed by alendronate compared to alendronate monotherapy and teriparatide followed by alendronate, in postmenopausal osteoporotic women at high risk of fracture, from a Belgian healthcare perspective. Romosozumab is reimbursed in Belgium since December 2021. METHODS: A Markov microsimulation model was used to evaluate the cost-effectiveness of romosozumab-to-alendronate compared to alendronate monotherapy and to teriparatide-to-alendronate over a lifetime horizon. Patients transition between five different health states every 6 months based on fracture risks or death. The model was populated with Belgium-specific epidemiological and cost data, where available. The fracture risk reduction of romosozumab treatment was collated from the ARCH study, and from a published network meta-analysis. Costs were included from a healthcare perspective (NIHDI). Cost-effectiveness was reported in terms of costs per quality-adjusted life year (QALY), reported in Euro (€) 2022. Deterministic (DSA) and probabilistic sensitivity analyses (PSA) were performed. RESULTS: Romosozumab-to-alendronate was associated with 0.12 additional QALYs at an additional cost of €2314 compared to alendronate monotherapy, resulting in an ICER of €19,978. Compared to teriparatide-to-alendronate, romosozumab-to-alendronate was found to be dominant, with higher QALYs and lower costs. The base-case results were robust to uncertainty in the input parameters when conducting the sensitivity analysis. CONCLUSION: Sequential treatment with romosozumab followed by alendronate was found to be cost-effective compared to alendronate monotherapy and dominant compared to teriparatide followed by alendronate for postmenopausal women with osteoporosis at high risk of fracture in Belgium.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Gielen E, Aldvén M, Kanis JA, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int. 2024. PMID: 38565690. doi:10.1007/s00198-024-07043-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。